贝利尤单抗治疗系统性红斑狼疮的短期临床观察  

Short-term clinical observation of Belimumab in the treatment of systemic lupus erythematosus

作　　者：许蕾 朱芸[2] 张昊 XU Lei;ZHU Yun;ZHANG Hao(Graduate School of Clinical Medicine,Weifang Medical University,Shandong Province,Weifang261053,China;Department of Rheumatology and Immunology,Weifang People’s Hospital,Shandong Province,Weifang261041,China)

机构地区：[1]潍坊医学院临床医学院研究生院,山东潍坊261053 [2]山东省潍坊市人民医院风湿免疫科,山东潍坊261041

出　　处：《中国医药导报》2021年第31期96-99,共4页China Medical Herald

基　　金：国家高技术研究发展计划(863计划)课题(2012AA02A513)。

摘　　要：目的探讨贝利尤单抗(Belimumab)治疗系统性红斑狼疮(SLE)的效果和安全性。方法选取2019年9月至2020年8月山东省潍坊市人民医院风湿免疫科确诊为SLE患者共42例,按照治疗方案将患者分为SoC(stand of care)组(仅使用标准治疗)21例、Belimumab组(标准治疗+Belimumab)21例。比较两组临床疗效,补体、免疫球蛋白G(IgG)的水平差异,并比较两组激素剂量、疾病活动度指数(SLEDAI)及不良事件。结果治疗后,Belimumab组总有效率高于SoC组,差异有统计学意义(P<0.05);两组C3、C4高于治疗前,IgG低于治疗前,Belimumab组补体C3、C4高于SoC组,IgG低于SoC组,差异有统计学意义(P<0.05);两组激素剂量比较,差异无统计学意义(P>0.05);两组SLEDAI评分低于治疗前,且Belimumab组低于SoC组,差异有统计学意义(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论贝利尤单抗应用于系统性红斑狼疮患者能提高治疗效果,具有安全性。Objective To evaluate the efficacy and safety of Belimumab in the treatment of systemic lupus erythematosus(SLE).Methods A total of 42 patients who were diagnosed with SLE from the Department of Rheumatology and Immunology,Weifang People’s Hospital from September 2019 to August 2020 were selected.According to the treatment regimen,patients were divided into SoC(stand of care)group(21 cases)and Belimumab group(21 cases)(standard treatment+Belimumab).The clinical efficacy,complement,immunoglobulin G(IgG)levels were compared between the two groups,hormone dose,disease activity index(SLEDAI),and,adverse events were compared between the two groups.Results After treatment,the total effective rate of Belimumab group was higher than that of SoC group,and the difference was statistically significant(P<0.05).C3 and C4 in the two groups were higher than before treatment,and IgG was lower than before treatment.Complement C3 and C4 in Belimumab group were higher than SoC group,and IgG was lower than SoC group,with statistical significance(P<0.05);there was no significant difference in hormone dose between the two groups(P>0.05),SLEDAI score of the two groups was lower than before treatment,and Belimumab group was lower than SoC group,the differences were statistically significant(P<0.05);there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Belizumab can improve the therapeutic effect in patients with systemic lupus erythematosus and is safe.

关 键 词：贝利尤单抗 系统性红斑狼疮 疾病活动度 治疗效果 

分 类 号：R593[医药卫生—内科学]